ANIKHealthcare · Drug Manufacturers - Specialty & GenericThe 2 Wall Street analysts covering Anika Therapeutics, Inc. hold a median 12-month price target of $23 — +6.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 27 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Anika Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Accruals (60): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ANIK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +6.7% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Sept 2026 | B. Riley Securities | Assumes | Buy | $21 → $23 |
| 30 July 2026 | B. Riley Securities | Maintains | Buy | — |
| 30 July 2026 | B. Riley Securities | Maintains | Buy | $18 → $21 |
| 27 Feb 2026 | Barrington Research | Maintains | Outperform | $16 → $17 |
| 27 Feb 2026 | Barrington Research | Maintains | Outperform | — |
| 9 Jan 2026 | Barrington Research | Maintains | Outperform | — |
| 6 Nov 2025 | Barrington Research | Maintains | Outperform | — |
| 23 Sept 2025 | Barrington Research | Maintains | Outperform | — |
| 31 July 2025 | Barrington Research | Maintains | Outperform | — |
| 12 May 2025 | Barrington Research | Maintains | Outperform | — |
| 13 Mar 2025 | Barrington Research | Maintains | Outperform | — |
| 1 Nov 2024 | Barrington Research | Maintains | Outperform | — |
| 22 Oct 2024 | Barrington Research | Maintains | Outperform | — |
| 9 Aug 2024 | Barrington Research | Maintains | Outperform | — |
| 29 May 2024 | Stephens & Co. | Reiterates | Equal-Weight | — |
| 9 May 2024 | Barrington Research | Maintains | Outperform | — |
| 14 Mar 2024 | Barrington Research | Maintains | Outperform | — |
| 14 Mar 2024 | Stephens & Co. | Reiterates | Equal-Weight | — |
| 3 Jan 2024 | Barrington Research | Maintains | Outperform | — |
| 3 Nov 2023 | Barrington Research | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ANIK appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, Anika Therapeutics, Inc. returned +121.3% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 97% of US stocks
Cheaper than 47% of US stocks
Cheaper than 41% of US stocks
Cheaper than 2% of US stocks
Higher than 64% of US stocks
Higher than 54% of US stocks
Higher than 78% of US stocks
Higher than 66% of US stocks
Higher than 26% of US stocks
Higher than 42% of US stocks
Higher than 40% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Anika Therapeutics, Inc. has a market value of $285.7M and an enterprise value of $272.6M.
Revenue in the twelve months to 30 June 2026: $120.7M. The latest quarter grew 15.6% year on year.
Net income over the same four quarters: −$3.8M, a −3.1% net margin.
Diluted earnings per share, trailing twelve months: $−0.27.
Free cash flow in the twelve months to 30 June 2026: $562K.
Anika Therapeutics, Inc. spent $15.1M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: −28.0×; forward P/E: 22.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Anika Therapeutics, Inc. employs 235 people — $513K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Anika Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Anika Therapeutics announced it will release its third-quarter 2026 financial results before market open on November 6, 2026. A conference call to discuss the results and business highlights is scheduled for 8:30 a.m. ET.
Why it matters — ANIK watchers can note the date and time when the company plans to report results and provide business updates.
A Zacks Investment Research piece compares the year-to-date stock performance of Anika Therapeutics (ANIK) and Concentra Group (CON) relative to their medical sector. The article evaluates how each company has fared against its industry peers so far this year.
Why it matters — This gives Anika watchers a direct performance comparison against a peer and the broader medical sector over the year.
On August 26th, 2026, Anika Therapeutics, Inc. (ANIK) was included in Zacks Investment Research's list of Zacks Rank #1 (Strong Buy) momentum stocks, alongside BTSG and OPHC.
Why it matters — For ANIK watchers, being named to Zacks' top momentum stock list is a notable external validation of the company's current market standing.
Zacks Investment Research highlighted Anika Therapeutics (ANIK) as a solid choice for shorter-term investors looking to capitalize on recent price trends, noting it passed the firm's shorter-term trading strategy-based screen.
Why it matters — The mention indicates that Anika's recent price trend, combined with its fundamental soundness, is being recognized by a stock-research screen.
Anika Therapeutics' stock has risen 43.4% over the past three months, driven by strong sales momentum and raised 2026 guidance. The company's pipeline is advancing with Cingal and Hyalofast, which have bolstered investor confidence.
Why it matters — ANIK watchers would care because the stock's significant gain, raised guidance, and pipeline progress signal strengthening company performance and growth prospects.
The 2 Wall Street analysts covering Anika Therapeutics, Inc. have a median 12-month price target of $23, with estimates ranging from $23 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Anika Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Anika Therapeutics, Inc. 99 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, Anika Therapeutics, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +6.7% from the last close, and Ticker Nerd's factor model ranks Anika Therapeutics, Inc. 99 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Anika Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANIK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $23 over the next 12 months.
Anika Therapeutics, Inc. returned +121.3% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Anika Therapeutics Inc. is a medical technology company focused on joint preservation and early intervention orthopedics.
The most recent item we track (GlobeNewsWire, 22 Oct 2026): "Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026". Anika Therapeutics announced it will release its third-quarter 2026 financial results before market open on November 6, 2026. A conference call to discuss the results and business highlights is scheduled for 8:30 a.m. ET.
Anika Therapeutics Inc. is a medical technology company focused on joint preservation and early intervention orthopedics. The company develops, manufactures, and commercializes hyaluronic acid-based products used in osteoarthritis pain management, regenerative medicine, sports medicine, and soft tissue repair. Its portfolio includes injectable therapies and orthopedic solutions designed to support mobility, tissue healing, and minimally invasive care for patients with degenerative joint conditions and musculoskeletal injuries. Anika Therapeutics serves healthcare professionals and clinical settings across the United States, Europe, and other international markets, with products used in orthopedics and related surgical applications. Headquartered in Bedford, Massachusetts, Anika Therapeutics Inc. plays a specialized role in the musculoskeletal care market by offering therapies and biomaterials that address joint health, cartilage repair, and recovery support.
CEO Mr. Stephen D. Griffin · 235 employees · United States · https://www.anika.com
